The focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) are protein tyrosine kinases that are overexpressed and activated in human breast cancer. To determine the role of EGFR and FAK survival signaling in breast cancer, EGFR was stably overexpressed in BT474 breast cancer cells, and each signaling pathway was specifically targeted for inhibition. 
INTRODUCTION
The invasion and metastasis of cancer requires a controlled process of basement membrane degradation, cellular motility, and anchorage-independent cellular survival. The process of metastasis requires a disseminating cancer cell to survive an environment that actively promotes apoptosis. Thus, for a cancer cell to effectively metastasize, it must possess survival signals that suppress apoptosis. One survival signal that recently has been shown to modulate apoptotic signaling is the focal adhesion kinase (FAK) (1) (2) (3) . This nonreceptor protein tyrosine kinase localizes to points of cell contact with the extracellular matrix (ECM), the focal adhesions (4, 5) .
FAK was originally isolated as a tyrosine phosphorylated 125 kDa protein in v-Srctransformed chicken embryo fibroblasts (6, 7) . FAK includes a N-terminal domain with a primary auto-phosphorylation site, tyrosine-397, that directly interacts with the Src-SH2 domain (8) , a central catalytic domain with major sites of phosphorylation Tyr-576/577, and a C-terminal domain with two proline-rich segments and a focal adhesion targeting subdomain (FAT) , that binds paxillin, talin, and other proteins (4, 9) . FAK activity is regulated by ECM receptors and integrins, and is involved in cellular processes such as spreading, motility, proliferation and survival (4, 10) . A non-catalytic domain of FAK, FAK-related nonkinase, FRNK (p41/p43) is expressed in chicken embryo cells (11) , initiated from an alternative promoter and start site residing within an intron (12) . Ectopic expression of FRNK caused dephosphorylation of FAK at Tyr-397 (13) and blocked FAK-mediated fibroblast migration (14) . (27) , (22) . However, another report suggests that FAK and EGFR are constitutively associated (26) . Thus, the relationship between EGFR signaling and FAK expression and activity during progression from noninvasive to an invasive and metastatic tumor phenotype is unknown, nor has their cooperation in preventing apoptosis been mechanistically examined.
In the present study, we examined the role of FAK and EGFR in survival signaling in a human breast cancer cell line model system of EGFR overexpression. We stably overexpressed EGFR in a cell line that endogenously overexpresses FAK (BT474-EGFR cells) to compare the effects of EGFR survival signaling with the parental cell line without
EGFR (BT474-pcDNA3 cells). We have demonstrated that dual inhibition of FAK and
EGFR cooperatively caused apoptosis in breast cancer cells. In breast cancer cells that stably overexpressed EGFR, there was a constitutive association between FAK and EGFR.
Furthermore, EGFR signaling suppressed death receptor-mediated apoptosis induced by FAK-CD. The mechanism included activation of AKT and ERK signaling pathways as well as protection of FAK from caspase degradation that was reversed by EGFR kinase inhibitor.
Dual inhibition of FAK by FAK-CD and EGFR by AG1478 cooperatively enhanced apoptosis in human breast cancer cell lines, via inhibition of signaling that involved both TNF family receptor-dependent AKT and ERK 1/2 pathways. This is the first report of the role of FAK and EGFR in apoptosis that shows that simultaneous inhibition of FAK and EGFR can be critical in induction of apoptosis in breast cancer cell lines. Cells and cell culture. BT474 breast carcinoma cells, described by Xu et al., (2) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 5 µg/ml insulin and 1 µg/ml penicillin/streptomycin. The clone of BT474 cell line used in this study had low expression of EGFR (Her-1) and Her-2.
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RESULTS

BT474-EGFR cells: EGF-dependent tyrosine phosphorylation and its inhibition by
AG1478.
To test the relationship between FAK and EGFR in breast cancer cell survival, we created a model system of EGFR overexpression in a clone of the BT474 breast carcinoma cell line (2), a cell line that expresses high levels of p125
FAK
, but minimal levels of EGFR.
Parental BT474 cells were stably transfected with the EGFR-pcDNA3 plasmid. These cells (called BT474-EGFR cells) expressed high levels of EGFR compared to the pcDNA3 vector control cells (called BT474-pcDNA3 cells) (Fig. 1A) . In BT474-EGFR cells, treatment with
11
EGF at a dose of 10 ng/ml rapidly increased EGFR tyrosine phosphorylation, and this effect was inhibited in the presence of the tyrphostin AG1478, an EGFR kinase inhibitor (Fig. 1B) .
The BT474-EGFR cells had a higher level of tyrosine phosphorylated cellular proteins than the vector control cells (Fig. 1C) , and both BT474-pcDNA3 and BT474-EGFR cells rapidly increased phosphorylation of ERK1/2 at 10 min upon EGF stimulation and reversed this effect by AG1478 treatment (Fig. 1D ). In addition, AKT (Ser-473) and FAK (pY397 and pY577) (not shown) were highly phosphorylated in BT474-EGFR cells.
FAK and EGFR constitutively associate in BT474-EGFR cells.
To test whether FAK and EGFR were associated in the BT474-EGFR cells, EGFR and FAK were immunoprecipitated using anti-FAK monoclonal antibody ( 
Inhibition of FAK and EGFR in BT474-EGFR cells downregulates both ERK1/2 and TNFR family dependent AKT survival pathways.
Since EGFR appeared to function as a survival signal to protect breast cancer cells Based on these data, EGFR not only signals through ERK1/2, but also has an effect on the ability of AKT to resist downregulation in response to FAK inhibition. To further examine the effects of EGFR on resistance to apoptosis, we tested whether overexpression of EGFR would protect the endogenous p125 FAK in the breast cancer cells from degradation in response to Ad-FAK-CD. Previous work from our group has shown that p125 FAK was degraded 24 hours after Ad-FAK-CD infection in parental BT474 cells, and this effect was mediated through caspases 8 and 3 (2) . Similarly, in these studies, the p125 (Fig. 5, lanes 6 and 7) . Co-infection of BT474 cells with Ad-FAK-CD and Ad-∆FADD, blocked cleavage of FAK (Fig. 5) .
In BT474-pcDNA3 cells, treatment with Ad-FAK-CD induced caspase-3 activation and PARP (caspase-3 substrate) cleavage (Fig. 6A) . Pretreatment of these cells with caspase-3 family inhibitor, Ac-DEVD-CHO peptide, prior to infection with Ad-FAK-CD blocked activation of caspase-3 and cleavage of PARP (Fig. 6A ) and increased the level of total AKT and FAK (Fig. 6 A) , indicating that reduction of AKT and FAK protein levels is the result of FAK and AKT cleavage by a caspase 3 pathway in the BT474 cells.
In contrast, overexpression of EGFR protected caspases 3 and 8 from degradation (Fig. 7A) .
However, inhibition of FAK and EGFR enhanced the levels of apoptosis in these cells ( Figure 7B ) in a similar fashion as seen in the BT474-EGFR cells (Fig. 4B) . At 46 hours after infection, the levels of apoptosis were slightly increased when cells were treated with FAK-CD and AG1478, compared to cells that had been treated with FAK-CD (7% versus 1.6%). However, at 71 hours, this effect was more apparent, where the apoptotic rate with FAK-CD alone was 10%, but addition of the EGFR kinase inhibitor increased the rate to 33% and 43% (-EGF and +EGF respectively) (Fig. 7B ).
Next, we directly compared the biochemical effects of FAK and EGFR inhibition between the BT474-EGFR cells and the BT-20 cells. As shown by control Ad-LacZ infection, the levels of endogenous EGFR and p125 FAK expression, as well as the levels of AKT phosphorylation were higher in the BT20 cells (Fig.8A, lanes 6 ) than in BT474-
pcDNA3 cells (lane 1) or the BT474-EGFR cells (lane 2). After 24 hours of infection with
Ad-FAK-CD, the BT-20 cells totally protected FAK from degradation detected in BT474-pcDNA3 cells (Fig.8A) . The ERK1/2 survival pathway was activated in BT20 cells, as in as BT20 cell have high levels of AKT (Fig. 8A) . At 72 hours after FAK-CD expression and in the presence of AG1478, BT20 cells detached and had down-regulated both ERK1/2 and AKT phosphorylation, and also downregulated total p125 FAK , caspase-3, and AKT proteins (Fig. 8 B) .
Next, we tested whether the degradation of FAK and AKT in the BT20 cells was DISCUSSION. an AKT-dependent mechanism as well as via an ERK1/2 pathway ( Figure 9 ). Dual inhibition of FAK and EGFR led to apoptosis via death receptor mediated signaling.
Individually, both FAK and EGFR have been shown to be overexpressed in human breast cancer specimens (15, 17, 18) . However, the relationship between these kinases and the subsequent cellular effects in breast cancer remain unclear. It has been shown that FAK and EGFR can associate when co-expressed in FAK-/-fibroblasts in the presence of EGF, suggesting that FAK can mediate a linkage between growth factor receptors and integrins (27) . Similarly, the association of FAK and EGFR has been shown in A431 epidermoid cancer cells (26) and A549 adenocarcinoma cells (22) , both of which express extraordinarily high levels of EGFR (50, 51 (22) . Other motility studies suggest that FAK is dephosphorylated in response to EGF, promoting tumor invasion and motility (26) . In studies of human glioblastoma cells, inhibition of FAK function by exogenously expressing the focal adhesion targeting domain also diminished EGFR-directed cell motility (19) . We have examined motility of the breast cancer cells in our system, and found that downregulation of FAK rapidly diminished both random and EGF-directed cell motility (data not shown), supporting the hypothesis that FAK is involved in EGF-directed motility pathways. Thus, the model proposed by Hauck et al. Our results in this study also support this hypothesis, whereby downregulation of FAK function had effects on apoptosis in EGFR-overexpressing breast cancer cells.
In these studies, the biochemical mechanisms of apoptotic resistance appeared to involve both the ERK and AKT pathways. Overexpression of EGFR was associated with a robust phosphorylation of ERK1/2 in the BT474-EGFR cells, and this appeared to augment the resistance to apoptosis induced by FAK downregulation. This is consistent with other studies implicating the ERK pathways in apoptotic resistance, including TNF-α induced apoptosis in fibrosarcoma cells (52), and stress-induced apoptosis in A431 cells (53) . In the These events appeared to activate the downstream caspase-8 and caspase-3 cascade with cleavage of important survival proteins as AKT and FAK (Fig. 9) . In EGFR and FAKpositive cells, binding of EGFR to FAK may partially block FAK-CD-induced apoptosis while EGFR itself can signal directly to AKT and ERK1/2. Furthermore, EGFR survival signaling was kinase-dependent, as inhibition of EGFR with AG1478 induced Ad-FAK-CD apoptosis ( Figure 9 ). In addition, the magnitude of these effects was cell type specific, as breast cancer cells such as BT20 that express high levels of FAK, EGFR, and AKT were more resistant to inhibition of these pathways than BT474 cells that expressed lower levels of these survival proteins.
Our model of survival signaling in the BT474-EGFR and BT-20 breast cancer cells is that there are multiple cross-talking signaling pathways via ERK and AKT that augment the resistance of tumor cells to the apoptotic-promoting effects of tumor dissemination. The persistent signaling to AKT and MAP kinase pathways, contributes to the resistance to apoptosis in these cells that overexpress EGFR. From these studies we conclude that FAK 23 and EGFR cooperatively suppress apoptosis in breast cancer cells, suggesting that targeting both signaling pathways will have an enhanced apoptotic effect in breast cancers that overexpress these kinases. 
FIGURE LEGENDS.
